Related Experiment Video
Updated: Feb 10, 2026

Cell-based Assay Protocol for the Prognostic Prediction of Idiopathic Scoliosis Using Cellular Dielectric Spectroscopy
Published on: October 16, 2013
Near final height in patients with idiopathic growth hormone deficiency: A single-centre experience
Erdal Kurnaz1, Semra Çetinkaya1, Zehra Aycan1
1Clinic of Pediatric Endocrinology, Dr. Sami Ulus Obstetrics and Gynecology and Pediatrics Training and Research Hospital, Ankara, Turkey.
Insights
Children with growth hormone deficiency (GHD) treated with recombinant human growth hormone (rhGH) can achieve near final height (NFH) within the mid-parental height range. Starting rhGH therapy during puberty may lead to greater height gains.
Area of Science:
- Pediatric Endocrinology
- Growth Hormone Therapy
- Genetics
Background:
- Growth hormone deficiency (GHD) impacts children's final height.
- Recombinant human growth hormone (rhGH) is a standard treatment for GHD.
- Understanding factors influencing near final height (NFH) is crucial for optimizing treatment outcomes.
Purpose of the Study:
- To analyze near final height (NFH) data in children with GHD treated with rhGH.
- To compare NFH outcomes between isolated GHD (IGHD) and multiple pituitary hormone deficiency (MPHD) groups.
- To evaluate the impact of pubertal status on rhGH treatment efficacy.
Main Methods:
- Retrospective analysis of NFH data in children with GHD receiving rhGH therapy.
- Patients were categorized into IGHD and MPHD groups.
- Data were further stratified by gender, pre-pubertal/pubertal status, and puberty type.
Main Results:
- rhGH therapy initiated at a median age of 12.1 years for IGHD and 9.1 years for MPHD.
- Height Standard Deviation Scores (SDSs) at therapy onset were significantly lower in the MPHD group.
- NFH SDSs were comparable between groups (-1.8 for IGHD, -1.6 for MPHD), but delta height SDSs were significantly higher in the MPHD group (2.6 vs 1.4).
- Total height gain was similar for pre-pubertal (1.4 SDS) and pubertal (1.3 SDS) starters.
Conclusions:
- Approximately 85% of patients achieved their genetic height potential.
- Greater height gains (delta height SDSs) were observed in patients initiating rhGH treatment during puberty.
- Achieving NFH within the mid-parental height range is feasible for patients starting rhGH therapy during puberty.
Aim:
We analysed near final height (NFH) data in children with growth hormone deficiency (GHD) treated with recombinant human GH (rhGH).
Methods:
We divided the idiopathic GHD patients into two groups, isolated GHD (IGHD) and multiple pituitary hormone deficiency, to evaluate NFH. Then, data were grouped according to gender, pre-pubertal/pubertal status and spontaneous or induced puberty. The trial was performed as a retrospective study. Median values are given, and measurements are expressed as standard deviation scores (SDSs).
Results:
rhGH therapy was started at a median age of 12.1 (range 9.1-14.9) years in the IGHD group (n = 162, 83 males) and 9.1 (range 4.9-13.4) years in the multiple pituitary hormone deficiency group (n = 33, 22 males) at a median dose of 0.20 mg/kg/week. Height SDSs at the onset of therapy were -3.2 (range -4.4 to -2.6) and -3.9 (-6.8 to -2.8) in the two groups, respectively (P < 0.001). NFH SDSs were -1.8 (-2.9 to -1) and -1.6 (-3.1 to -0.4) (P = 0.139), and delta height SDSs (finish - start) were 1.4 (0.3-2.5) and 2.6 (1.5-4.6) (P < 0.001), respectively. Total delta height was 1.4 SDS (0.4-3.1) in patients who started rhGH treatment in the pre-pubertal period and 1.3 SDS (0.3-2.4) (P = 0.106) in those who started rhGH in the pubertal period.
Conclusions:
About 85% of the cases reached their genetic height potential. Delta height SDSs were higher than expected in cases that started treatment during the pubertal period. Therefore, it is possible to achieve NFH within the mid-parental height range in patients who start therapy during puberty.
More Related Videos
06:36A Modified In vitro Invasion Assay to Determine the Potential Role of Hormones, Cytokines and/or Growth Factors in Mediating Cancer Cell Invasion
Published on: April 24, 2015
07:26Designing Automated, High-throughput, Continuous Cell Growth Experiments Using eVOLVER
Published on: May 19, 2019
Related Concept Videos
Types of Hormones
Types of Hormones
Steroids and eicosanoids fall under the category of lipid-soluble hormones. Steroids are derived from cholesterol and feature four interconnected carbon rings with variable side chains. Notable examples include estradiol from ovaries and testosterone from testes, exemplifying the critical roles of these lipid-soluble hormones in reproductive physiology. Eicosanoids, derived...
Plant Hormones
Hormonal Regulation
Hormonal Regulation
Primary and Secondary Growth in Roots and Shoots